Stroke survivors: which statin combo cuts recurrence best?

NCT ID NCT06360120

Recruiting now Disease control Sponsor: Kafrelsheikh University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial compares atorvastatin versus rosuvastatin, both given with clopidogrel, in 600 adults who had a first large-vessel ischemic stroke. The goal is to see which combination better prevents new strokes within 90 days. Participants receive either 40 mg atorvastatin or 40 mg rosuvastatin daily for 3 months, plus clopidogrel. The study tracks stroke recurrence and disability scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atorvastatin, rosuvastatin, and clopidogrel
What this could lead to: If it works, this could show that one statin is better than the other at preventing another stroke when combined with clopidogrel.
What could go wrong: This is a single-blinded trial, so expectations may be biased. The results may not apply to all stroke types, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke large artery stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE

Contacts and locations

Locations

Kafr Elsheikh University Hospital
RECRUITING

Kafr ash Shaykh, 33511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.